Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
23 hedge funds and large institutions have $9.16M invested in Interpace Biosciences, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.
6% more capital invested
Capital invested by funds: $8.68M → $9.16M (+$488K)
4% less funds holding
Funds holding: 24 → 23 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$420K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$75.5K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$16.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.58K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$115K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$43K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$3.47K |
IDXG Hedge Fund Activity: Q2 2015 in Review
23 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2015, worth a combined $9.16M — up 5.6% from $8.68M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IDXG and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Ancora Advisors, opening a new position worth an estimated $420K. The largest seller was Pekin Hardy Strauss, cutting an estimated $115K.
- 23 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2015, down from 24 in Q1 2015.
- Funds reported $9.16M of Interpace Biosciences, Inc. Common Stock stock for Q2 2015, up 5.6% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2015 and 5 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2015 was Ancora Advisors, an estimated $420K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2015 was Pekin Hardy Strauss, an estimated $115K sold.
Based on aggregated 13F filings for Q2 2015.